Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib PK with Itraconazole
NCT02259010Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in solid tumor and lymphoma, sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Concentration of Alisertib at Day 10, Area Under the Plasma Concentration Curve From Time 0 to Last Quantifiable Concentration at Day 10 and 1 more. Started Oct 2014; status: completed.
02
Drugs
alisertib
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02259010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259010.